Latest & greatest articles for depression

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on depression or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on depression and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for depression

181. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. (PubMed)

Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. Importance: Major depressive disorder (MDD) is prevalent among patients with chronic kidney disease (CKD) and is associated with morbidity and mortality. The efficacy and adverse events of selective serotonin reuptake inhibitors in these patients are unknown. Objective: To determine whether treatment with sertraline improves depressive symptoms (...) run-in, participants were randomized to sertraline (n = 102) for 12 weeks at an initial dose of 50 mg/d (escalated to a maximum dose of 200 mg/d based on tolerability and response) or matching placebo (n = 99). Main Outcomes and Measures: The primary outcome was improvement in depressive symptom severity from baseline to 12 weeks determined by the 16-item Quick Inventory of Depression Symptomatology-Clinician Rated (QIDS-C16) (score range, 0-27; minimal clinically important difference, 2 points

Full Text available with Trip Pro

2017 JAMA

183. Gabapentin (Neurontin): risk of severe respiratory depression

Gabapentin (Neurontin): risk of severe respiratory depression Gabapentin (Neurontin): risk of severe respiratory depression - GOV.UK GOV.UK uses cookies to make the site simpler. Search Gabapentin (Neurontin): risk of severe respiratory depression From: Published: 26 October 2017 Therapeutic area: and Gabapentin has been associated with a rare risk of severe respiratory depression even without concomitant opioid medicines. Patients with compromised respiratory function, respiratory (...) or neurological disease, renal impairment, concomitant use of central nervous system (CNS) depressants, and elderly people might be at higher risk of experiencing severe respiratory depression. Dose adjustments might be necessary in these patients. Contents Advice for healthcare professionals: be aware of the risk of CNS depression, including severe respiratory depression, with gabapentin consider whether dose adjustments might be necessary in patients at higher risk of respiratory depression, including

2017 MHRA Drug Safety Update

184. Sustained effectiveness and cost-effectiveness of the Healthy Activity Programme, a brief psychological treatment for depression delivered by lay counsellors in primary care: 12-month follow-up of a randomised controlled trial (PubMed)

Sustained effectiveness and cost-effectiveness of the Healthy Activity Programme, a brief psychological treatment for depression delivered by lay counsellors in primary care: 12-month follow-up of a randomised controlled trial 28898283 2017 09 12 2017 09 21 2017 09 21 1549-1676 14 9 2017 Sep PLoS medicine PLoS Med. Sustained effectiveness and cost-effectiveness of the Healthy Activity Programme, a brief psychological treatment for depression delivered by lay counsellors in primary care: 12 (...) -month follow-up of a randomised controlled trial. e1002385 10.1371/journal.pmed.1002385 The Healthy Activity Programme (HAP), a brief behavioural intervention delivered by lay counsellors, enhanced remission over 3 months among primary care attendees with depression in peri-urban and rural settings in India. We evaluated the sustainability of the effects after treatment termination, the cost-effectiveness of HAP over 12 months, and the effects of the hypothesized mediator of activation on clinical

Full Text available with Trip Pro

2017 EvidenceUpdates

185. Socioeconomic status indicators and common mental disorders: Evidence from a study of prenatal depression in Pakistan (PubMed)

Socioeconomic status indicators and common mental disorders: Evidence from a study of prenatal depression in Pakistan 29349268 2018 11 13 2352-8273 4 2018 Apr SSM - population health SSM Popul Health Socioeconomic status indicators and common mental disorders: Evidence from a study of prenatal depression in Pakistan. 1-9 10.1016/j.ssmph.2017.10.004 There is growing interest in the relationship between socioeconomic status (SES), poverty, and mental health in low and middle-income countries (...) (LMIC). However, it is not clear whether a gradient approach focused on a wider SES distribution or a binary poverty approach is more salient for mental health in LMIC. Yet this distinction has implications for interventions aimed at improving population health. We contribute to the literature by examining how multiple indicators of socioeconomic status, including gradient SES and binary poverty indicators, contribute to prenatal depression symptoms in a LMIC context. Prenatal depression

Full Text available with Trip Pro

2017 SSM - population health

186. Desvenlafaxine versus Venlafaxine for the Treatment of Adult Patients with Major Depressive Disorder: A Review of the Comparative Clinical and Cost-Effectiveness

Desvenlafaxine versus Venlafaxine for the Treatment of Adult Patients with Major Depressive Disorder: A Review of the Comparative Clinical and Cost-Effectiveness Desvenlafaxine versus Venlafaxine for the Treatment of Adult Patients with Major Depressive Disorder: A Review of the Comparative Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Desvenlafaxine versus Venlafaxine for the Treatment of Adult Patients with Major Depressive Disorder: A Review of the Comparative (...) Clinical and Cost-Effectiveness Desvenlafaxine versus Venlafaxine for the Treatment of Adult Patients with Major Depressive Disorder: A Review of the Comparative Clinical and Cost-Effectiveness Published on: October 25, 2017 Project Number: RC0921-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of desvenlafaxine versus venlafaxine for the treatment of adult patients with Major Depressive

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

187. The role of anxiety and depression on acceptance and action, considering emotional schemas in diabetics of Birjand (Iran) (PubMed)

The role of anxiety and depression on acceptance and action, considering emotional schemas in diabetics of Birjand (Iran) 29238497 2018 11 13 2008-5842 9 10 2017 Oct Electronic physician Electron Physician The role of anxiety and depression on acceptance and action, considering emotional schemas in diabetics of Birjand (Iran). 5551-5559 10.19082/5551 Diabetes is one of the most common noncommunicable diseases around the world that accompanies assorted psychiatric disorders including anxiety (...) and depression due to being chronic. The aim of this study was to evaluate the effect of anxiety and depression on acceptance and action, considering emotional schemas of diabetics referring to diabetes clinics of health centers in Birjand, Iran. This study was conducted in 2016 and was a correlational study with a structural equation modeling approach. The statistical population of this study were all men and women with type 2 diabetes in Birjand, with an active health record in health centers

Full Text available with Trip Pro

2017 Electronic physician

188. Acceptability of the Fitbit in behavioural activation therapy for depression: a qualitative study (PubMed)

Acceptability of the Fitbit in behavioural activation therapy for depression: a qualitative study 29056608 2018 08 03 2018 11 13 1468-960X 20 4 2017 Nov Evidence-based mental health Evid Based Ment Health Acceptability of the Fitbit in behavioural activation therapy for depression: a qualitative study. 128-133 10.1136/eb-2017-102763 Major depressive disorder is characterised by low mood and poor motivation. Literature suggests that increased physical activity has positive effects on alleviating (...) depression. Fitness-tracking devices may complement behavioural activation (BA) therapy to improve physical activity and mental health in patients with depression. To understand patients' perceived benefit from the Fitbit and explore themes associated with patient experiences. To compare perceived benefit, patient factors, Fitbit usage and Beck's Depression Inventory (BDI) scores. Semistructured interviews were conducted with patients (n=36) who completed a 28-week BA group programme in a mood disorders

Full Text available with Trip Pro

2017 Evidence-Based Mental Health

189. Prevalence of anxiety, depression and post-traumatic stress disorder in the Kashmir Valley (PubMed)

Prevalence of anxiety, depression and post-traumatic stress disorder in the Kashmir Valley 29082026 2018 11 13 2059-7908 2 4 2017 BMJ global health BMJ Glob Health Prevalence of anxiety, depression and post-traumatic stress disorder in the Kashmir Valley. e000419 10.1136/bmjgh-2017-000419 Following the partition of India in 1947, the Kashmir Valley has been subject to continual political insecurity and ongoing conflict, the region remains highly militarised. We conducted a representative cross (...) -sectional population-based survey of adults to estimate the prevalence and predictors of anxiety, depression and post-traumatic stress disorder (PTSD) in the 10 districts of the Kashmir Valley. Between October and December 2015, we interviewed 5519 out of 5600 invited participants, ≥18 years of age, randomly sampled using a probability proportional to size cluster sampling design. We estimated the prevalence of a probable psychological disorder using the Hopkins Symptom Checklist (HSCL-25

Full Text available with Trip Pro

2017 BMJ global health

190. Depression, quality of life, and medical resource utilization in sickle cell disease (PubMed)

Depression, quality of life, and medical resource utilization in sickle cell disease 29296845 2018 11 13 2473-9529 1 23 2017 Oct 24 Blood advances Blood Adv Depression, quality of life, and medical resource utilization in sickle cell disease. 1983-1992 10.1182/bloodadvances.2017006940 Sickle cell disease (SCD) is a chronic, debilitating disorder. Chronically ill patients are at risk for depression, which can affect health-related quality of life (HRQoL), health care utilization, and cost. We (...) performed an analytic epidemiologic prospective study to determine the prevalence of depression in adult patients with SCD and its association with HRQoL and medical resource utilization. Depression was measured by the Beck Depression Inventory and clinical history in adult SCD outpatients at a comprehensive SCD center. HRQoL was assessed using the SF36 form, and data were collected on medical resource utilization and corresponding cost. Neurocognitive functions were assessed using the CNS Vital Signs

Full Text available with Trip Pro

2017 Blood advances

191. Stability of Cortical Thinning in Persons at Increased Familial Risk for Major Depressive Disorder Across 8 Years (PubMed)

Stability of Cortical Thinning in Persons at Increased Familial Risk for Major Depressive Disorder Across 8 Years 29085917 2018 11 13 2451-9030 2 7 2017 Oct Biological psychiatry. Cognitive neuroscience and neuroimaging Biol Psychiatry Cogn Neurosci Neuroimaging Stability of Cortical Thinning in Persons at Increased Familial Risk for Major Depressive Disorder Across 8 Years. 619-625 10.1016/j.bpsc.2017.04.009 A biological marker of vulnerability should precede onset of illness (...) and be independent of disease course. We previously reported that cortical thinning may serve as a potential biomarker for risk for familial depression. We now test stability of the cortical thinning across 8 years, and whether thinning mediates associations between familial risk and depressive traits. Participants were from a 3-generation family study of depression, where 2nd and 3rd generation offspring were characterized as being at high- or low-risk for depression based on the presence/absence of major

Full Text available with Trip Pro

2017 Biological psychiatry. Cognitive neuroscience and neuroimaging

192. Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment (PubMed)

Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment 29034354 2018 11 13 2451-9030 2 7 2017 Oct Biological psychiatry. Cognitive neuroscience and neuroimaging Biol Psychiatry Cogn Neurosci Neuroimaging Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment. 566-574 10.1016/j.bpsc.2017.04.006 Prefrontal global brain connectivity with global signal regression (GBCr (...) ) was proposed as a robust biomarker of depression, and was associated with ketamine's mechanism of action. Here, we investigated prefrontal GBCr in treatment-resistant depression (TRD) at baseline and following treatment. Then, we conducted a set of pharmacological challenges in healthy subjects to investigate the glutamate neurotransmission correlates of GBCr. In study A, we used functional magnetic resonance imaging ( f MRI) to compare GBCr between 22 TRD and 29 healthy control. Then, we examined

Full Text available with Trip Pro

2017 Biological psychiatry. Cognitive neuroscience and neuroimaging

193. Cost and Outcome of BehaviouRal Activation (COBRA): a randomised controlled trial of behavioural activation versus cognitive behavioural therapy for depression

Cost and Outcome of BehaviouRal Activation (COBRA): a randomised controlled trial of behavioural activation versus cognitive behavioural therapy for depression Cost and Outcome of BehaviouRal Activation (COBRA): a randomised controlled trial of behavioural activation versus cognitive behavioural therapy for depression Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found (...) . Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} Behavioural activation therapy was as effective and more cost effective than CBT for people with depression and can be delivered by mental health workers with no professional training in psychological therapies {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , , , , & . David A Richards

2017 NIHR HTA programme

194. Depression

Depression Depression | ONS Search the ONS website Depression Depression PEP Topics Depression Symptoms such as depressed mood, diminished interest or pleasure in activities that were previously enjoyed, loss of energy, feeling of worthlessness or guilt, diminished ability to think or concentrate, and recurrent thoughts of death or suicide are indicative of depression. Depressive symptoms in people with cancer may be attributed to the diagnosis of cancer or side effects of cancer treatment

2017 Oncology Nursing Society Putting Evidence into Practice (PEP)

195. Subgenual Anterior Cingulate-Medial Orbitofrontal Functional Connectivity in Medication-Resistant Major Depression: A Neurobiological Marker for Accelerated Intermittent Theta Burst Stimulation Treatment? (PubMed)

Subgenual Anterior Cingulate-Medial Orbitofrontal Functional Connectivity in Medication-Resistant Major Depression: A Neurobiological Marker for Accelerated Intermittent Theta Burst Stimulation Treatment? 29560909 2018 12 04 2451-9030 2 7 2017 10 Biological psychiatry. Cognitive neuroscience and neuroimaging Biol Psychiatry Cogn Neurosci Neuroimaging Subgenual Anterior Cingulate-Medial Orbitofrontal Functional Connectivity in Medication-Resistant Major Depression: A Neurobiological Marker (...) for Accelerated Intermittent Theta Burst Stimulation Treatment? 556-565 S2451-9022(17)30003-4 10.1016/j.bpsc.2017.01.001 Accelerated repetitive transcranial magnetic stimulation paradigms have been shown to result in fast decreases in depressive symptoms and suicidal ideation. Although the subgenual anterior cingulate cortex (sgACC) region has been put forward as a possible biological marker, so far, no studies evaluated the clinical effects of accelerated intermittent theta burst stimulation (aiTBS) on sgACC

2017 Biological psychiatry. Cognitive neuroscience and neuroimaging

196. Depressed patients with heart failure may not improve with escitalopram

Depressed patients with heart failure may not improve with escitalopram Depressed patients with heart failure may not improve with escitalopram Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Depressed patients with heart failure may not improve with escitalopram View/ Open Date 2017-07 Format Metadata Abstract Bottom (...) line: Escitalopram does not decrease mortality, rehospitalization rates, or depression symptoms among depressed patients with heart failure. This conclusion may not apply to all depressed patients and the study population was not large enough to definitively rule out a benefit in depression symptoms. URI Part of Citation Evidence-based practice 20, no. 7 (2017): E13 Collections hosted by hosted by

2017 Evidence Based Practice

197. Essential Tremor and Depression (PubMed)

Essential Tremor and Depression 29805986 2018 11 14 2330-1619 4 6 2017 Nov-Dec Movement disorders clinical practice Mov Disord Clin Pract Essential tremor and depression. 838-842 10.1002/mdc3.12530 Depression and neuropsychiatric disorders in individuals with essential tremor (ET) are not well characterized in the literature. We compared 104 ET subjects with 481 non-ET controls involved in the Arizona Study of Aging and Neurodegenerative Disorders. An analysis of baseline depression scales (...) with subjectively distressing tremor compared with those without. There were no significant differences in depressive symptoms between ET and non-ET groups. Furthermore, no correlation was found between depressive symptoms in ET groups based on tremor severity, duration, or age of onset. Aslam Sana S Barrow Neurological Institute, Phoenix, AZ. Zhang Nan N Mayo Clinic Arizona, Scottsdale, AZ. Adler Charles H CH Mayo Clinic Arizona, Scottsdale, AZ. Caviness John N JN Mayo Clinic Arizona, Scottsdale, AZ. Driver

Full Text available with Trip Pro

2017 Movement disorders clinical practice

198. Trajectories of change and long-term outcomes in a randomised controlled trial of internet-based insomnia treatment to prevent depression (PubMed)

Trajectories of change and long-term outcomes in a randomised controlled trial of internet-based insomnia treatment to prevent depression 28959453 2018 11 13 2056-4724 3 5 2017 Sep BJPsych open BJPsych Open Trajectories of change and long-term outcomes in a randomised controlled trial of internet-based insomnia treatment to prevent depression. 228-235 10.1192/bjpo.bp.117.005231 Insomnia treatment using an internet-based cognitive-behavioural therapy for insomnia (CBT-I) program reduces (...) depression symptoms, anxiety symptoms and suicidal ideation. However, the speed, longevity and consistency of these effects are unknown. To test the following: whether the efficacy of online CBT-I was sustained over 18 months; how rapidly the effects of CBT-I emerged; evidence for distinct trajectories of change in depressive symptoms; and predictors of these trajectories. A randomised controlled trial compared the 6-week Sleep Healthy Using the Internet (SHUTi) CBT-I program to an attention control

Full Text available with Trip Pro

2017 BJPsych open

199. Predictors, help-seeking behaviour and treatment coverage for depression in adults in Sehore district, India (PubMed)

Predictors, help-seeking behaviour and treatment coverage for depression in adults in Sehore district, India 28904815 2018 11 13 2056-4724 3 5 2017 Sep BJPsych open BJPsych Open Predictors, help-seeking behaviour and treatment coverage for depression in adults in Sehore district, India. 212-222 10.1192/bjpo.bp.116.004648 National Mental Health Survey found that in India, the point prevalence of major depressive disorder (MDD) was 2.7% and the treatment gap was 85.2%, whereas in Madhya Pradesh (...) the point prevalence of MDD was 1.4% and the treatment gap was 80%. To describe the baseline prevalence of depression among adults, association of various demographic and socioeconomic variables with depression and estimation of contact coverage for the same. Population-based cross-sectional survey of 3220 adults in Sehore district of Madhya Pradesh, India. The outcome of interest was a probable diagnosis of depression that was measured using the Patient Health Questionnaire (PHQ-9) and the proportion

Full Text available with Trip Pro

2017 BJPsych open

200. The Relationship between Parental Rearing Behavior, Resilience, and Depressive Symptoms in Adolescents with Congenital Heart Disease (PubMed)

The Relationship between Parental Rearing Behavior, Resilience, and Depressive Symptoms in Adolescents with Congenital Heart Disease 28944224 2018 11 13 2297-055X 4 2017 Frontiers in cardiovascular medicine Front Cardiovasc Med The Relationship between Parental Rearing Behavior, Resilience, and Depressive Symptoms in Adolescents with Congenital Heart Disease. 55 10.3389/fcvm.2017.00055 Parental rearing behavior is one factor that influences the strength of resilience. In turn, resilience (...) influences depression. However, it is unclear whether resilience has a mediating effect on the relationship between parental rearing and depression in adolescents with congenital heart disease (CHD). Therefore, the associations between parental rearing behavior and resilience and between rearing behavior and symptoms of depression were investigated with respect to age, gender and disease severity. Patients completed a parental rearing behavior questionnaire, a resilience scale and the Children's

Full Text available with Trip Pro

2017 Frontiers in cardiovascular medicine